Pure Biologics Spólka Akcyjna (PUR.WA)

PLN 9.19

(-3.26%)

Operating Expenses Summary of Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna's latest annual operating expenses in 2023 was 29.14 Million PLN , up 41.3% from previous year.
Pure Biologics Spólka Akcyjna's latest quarterly operating expenses in 2024 Q2 was -640 Thousand PLN , down -110.96% from previous quarter.
Pure Biologics Spólka Akcyjna reported a annual operating expenses of 19.27 Million PLN in annual operating expenses 2022, up 198.37% from previous year.
Pure Biologics Spólka Akcyjna reported a annual operating expenses of 6.46 Million PLN in annual operating expenses 2021, down -45.51% from previous year.
Pure Biologics Spólka Akcyjna reported a quarterly operating expenses of 4.34 Million PLN for 2024 Q1, down -42.66% from previous quarter.
Pure Biologics Spólka Akcyjna reported a quarterly operating expenses of 5.66 Million PLN for 2023 Q3, down -34.21% from previous quarter.

Annual Operating Expenses Chart of Pure Biologics Spólka Akcyjna (2023 - 2016)

Historical Annual Operating Expenses of Pure Biologics Spólka Akcyjna (2023 - 2016)

Year	Operating Expenses	Operating Expenses Growth
2023	29.14 Million PLN	41.3%
2022	19.27 Million PLN	198.37%
2021	6.46 Million PLN	-45.51%
2020	11.85 Million PLN	-30.92%
2019	17.16 Million PLN	134.39%
2018	7.32 Million PLN	479.0%
2017	1.26 Million PLN	-17.28%
2016	1.52 Million PLN	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	-640 Thousand PLN	-110.96%
2024 Q1	4.34 Million PLN	-42.66%
2023 Q3	5.66 Million PLN	-34.21%
2023 Q4	7.57 Million PLN	33.64%
2023 Q1	5.38 Million PLN	2.94%
2023 Q2	8.61 Million PLN	59.84%
2023 FY	27.23 Million PLN	41.3%
2022 Q2	4.52 Million PLN	6.25%
2022 Q4	5.23 Million PLN	-0.46%
2022 FY	19.27 Million PLN	198.37%
2022 Q1	4.25 Million PLN	199.91%
2022 Q3	5.25 Million PLN	16.22%
2021 Q1	3.06 Million PLN	-32.71%
2021 FY	6.46 Million PLN	-45.51%
2021 Q3	4.13 Million PLN	17.4%
2021 Q4	-4.26 Million PLN	-203.05%
2021 Q2	3.52 Million PLN	15.02%
2020 Q4	4.55 Million PLN	77.4%
2020 FY	11.85 Million PLN	-30.92%
2020 Q2	2.53 Million PLN	-50.12%
2020 Q3	2.56 Million PLN	1.26%
2020 Q1	5.07 Million PLN	-9.62%
2019 Q2	4.23 Million PLN	40.44%
2019 Q1	3.01 Million PLN	9.42%
2019 FY	17.16 Million PLN	134.39%
2019 Q4	5.62 Million PLN	31.23%
2019 Q3	4.28 Million PLN	1.03%
2018 Q3	1.92 Million PLN	29.97%
2018 FY	7.32 Million PLN	479.0%
2018 Q1	1.16 Million PLN	171.23%
2018 Q2	1.47 Million PLN	27.53%
2018 Q4	2.75 Million PLN	43.45%
2017 Q3	173.26 Thousand PLN	0.0%
2017 FY	1.26 Million PLN	-17.28%
2017 Q4	427.75 Thousand PLN	146.87%
2016 FY	1.52 Million PLN	0.0%

Peer Operating Expenses Comparison of Pure Biologics Spólka Akcyjna

Name	Operating Expenses	Operating Expenses Difference
Bioceltix S.A.	15.38 Million PLN	-89.434%
BIOTON S.A.	57.55 Million PLN	49.366%
Captor Therapeutics Spolka Akcyjna	79.91 Million PLN	63.532%
Mabion S.A.	59.52 Million PLN	51.037%
Molecure S.A.	31.73 Million PLN	8.151%
NanoGroup S.A.	7.82 Million PLN	-272.369%
Pharmena S.A.	-32.76 Million PLN	188.949%
Poltreg S.A.	15.47 Million PLN	-88.33%
Ryvu Therapeutics S.A.	4.73 Million PLN	-515.112%
Synthaverse S.A.	26.35 Million PLN	-10.587%
Urteste S.A.	5.96 Million PLN	-388.338%